Janux Therapeutics Inc
JANX
Company Profile
Business description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Contact
10955 Vista Sorrento Parkway
Suite 200
San DiegoCA92130
USAT: +1 858 751-4493
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
103
Stocks News & Analysis
stocks
Palantir earnings: AI leadership intact; valuation still causes heartburn
Our view of Palantir Technologies.
stocks
As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally
Demand for AI has catapulted tech stocks into the stratosphere.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.20 | 19.30 | -0.21% |
| CAC 40 | 8,074.23 | 6.70 | 0.08% |
| DAX 40 | 24,048.87 | 99.76 | 0.42% |
| Dow JONES (US) | 47,193.08 | 107.84 | 0.23% |
| FTSE 100 | 9,777.08 | 62.12 | 0.64% |
| HKSE | 25,935.41 | 16.99 | -0.07% |
| NASDAQ | 23,557.04 | 208.40 | 0.89% |
| Nikkei 225 | 50,212.27 | 1,284.93 | -2.50% |
| NZX 50 Index | 13,620.98 | 15.02 | 0.11% |
| S&P 500 | 6,811.87 | 40.32 | 0.60% |
| S&P/ASX 200 | 8,802.00 | 7.80 | -0.09% |
| SSE Composite Index | 3,969.25 | 9.06 | 0.23% |